MedTrace Logo

Characterization of Prostate Cancer With 3T MR

NCT00831142 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 236

Last updated 2024-04-26

No results posted yet for this study

Summary

The long-term goal of this proposal is to provide a pre-treatment evaluation that can assist in the rational selection of patients to undergo appropriate and definitive therapy for prostate cancer. In so doing, it may be possible to further improve the numbers and percentage of cancer patients who receive effective therapy that will cure the disease and maximize their quality of life following therapy.

* Aim 1: To evaluate the accuracy of T2W MRI, DCE-MRI and their combined data for staging prostate cancer.
* Aim 2: To evaluate the accuracy of MRI in determining tumor volume in the prostate gland.
* Aim 3: To evaluate the accuracy of MRI in grading prostate cancer.

Conditions

Sponsors & Collaborators

Principal Investigators

  • David C Alsop, PhD · Beth Israel Deaconess Medical Center

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2012-01-31
Completion
2025-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00831142 on ClinicalTrials.gov